Name | Type | Posted | Actions |
|---|---|---|---|
RFP 75A50121R00013 Pages 1-2 9-10-2021.pdf | Sep 10, 2021 | ||
Amendment 4 - Summary.pdf | Sep 10, 2021 | ||
RFP SOW-New Stockpile Updated with Responses 9-2-2021.pdf | Sep 3, 2021 | ||
New Email Account 8-29-2021.pdf | Aug 29, 2021 | ||
Amendment 3 - Past Performance Update v1.pdf | Aug 26, 2021 | ||
Amendment 3 - Past Performance Update.pdf | Aug 25, 2021 | ||
Response - Proposal Ext.pdf | Aug 18, 2021 | ||
QA for Follow-On Stockpile - Additional Questions - 8-16-21 FINAL .pdf | Aug 17, 2021 | ||
QA for Follow Stockpile - IDIQ 8-6-21 FINAL.pdf | Aug 7, 2021 | ||
Amendment 2 - Summary.docx | DOCX | Jul 26, 2021 | |
RFP SOW-New Stockpile 6-29-2021 - Amendment 1.pdf | Jul 23, 2021 | ||
Amendment 1 - Summary.pdf | Jul 23, 2021 | ||
RFP SOW-New Stockpile 6-29-2021 - Program Updated - CLEAN.pdf | Jun 29, 2021 |
Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response
Contact and place of performance
Wendell Conyers
DC
USA
Reference Amendment 1 PERIOD OF PERFORMANCE a. The base period of performance of this contract is anticipated for thirty-six (36) monthsfrom date of award. The period of performance may be extended up to 24 months withthe exercise of option(s), structured as CLINs. b. If the Government exercises its option(s), the period of performance will be increased as listed below: Option I Twelve (12) Months (Year 4) Option II...
View moreThe Office of the Assistant Secretary for Preparedness and Response (ASPR), through the Biomedical Advanced Research and Development Authority (BARDA) Division of Contracts Management and Acquisition, is seeking medical countermeasures for pandemic influenza and emerging diseases. This combined synopsis and solicitation, identified by solicitation number 75A50121R00013, requires the manufacturing, storage, and testing of biological products to support public health preparedness. The primary classification for this effort is NAICS 325414 Biological Product (except Diagnostic) Manufacturing and PSC 6505 Drugs and Biologicals. Performance is located in Washington, D.C., and responses are due by September 13, 2021.
The scope of work encompasses the production of cGMP influenza vaccine master and working seed lots, research and investigational lots, and commercial scale bulk lots. Additional requirements include clinical and commercial scale bulk adjuvants, formulation and filling services for various delivery systems, and comprehensive storage and stability testing for antigens and adjuvants. The contractor must also provide candidate vaccine viruses, potency reagents, analytical laboratory testing, and non-clinical and clinical studies. Specialized tasks for emerging pathogens and the disposal of products may be assigned through subsequent Requests for Task Order Responses (RTOR).
The anticipated contract features a 36-month base period of performance with two 12-month options, potentially extending the total duration to 60 months. A minimum guarantee of $50,000.00 is established for the duration of the contract, including all options. Most contract line items are structured as firm-fixed-price, though specific CLINs for shipping, disposal, and clinical studies will be determined through future task orders. Thirteeen attachments are associated with this notice, including multiple amendments, a statement of work updated as of September 2, 2021, and information regarding a new email account for submissions.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.